6/28/23, 12:22 AM CREDENCE Pathway Feedback Search Clinical Topics Home Studies CREDENCE CREDENCE Disease Disease Chronic kidney disease Diabetes mellitus type 2 Trial question What is the role of canagliflozin in patients with T2DM and kidney disease? Study design Multi-center Double blinded RCT Population Characteristics of study participants 34.0% female N = 4401 66.0% male 4401 patients (1494 female, 2907 male) Inclusion criteria: patients with T2DM and kidney disease Key exclusion criteria: diabetic ketoacidosis, T1DM mellitus, renal transplant, chronic dialysis, uncontrolled hypertension, myocardial infarction, unstable angina, revascularization procedure Interventions N=2202 canagliflozin (100 mg PO once daily) N=2199 placebo (matching tablet) Primary outcome Incidence of ESRD, doubling of creatinine, renal death, or CV death 6.1 % / y 6.1 4.6 % / y 4.3 3 0 % / y https://web.pathway.md/studies/recNvS32Ff41qxbEc 1/2 6/28/23, 12:22 AM 3.0 % / y CREDENCE Pathway 1.5 % / y Significant decrease 0.0 % / y Canagliflozin Placebo Significant decrease in the incidence of ESRD, doubling of creatinine, renal death, or CV death (4.3% / y vs. 6.1% / y; HR 0.7, 95% CI 0.59 to 0.82) Secondary outcomes No significant difference in death from any cause (5.8% vs. 9.1%; HR 0.83, 95% CI 0.68 to 1.02) Significant decrease in CV death or hospitalization for HF (5.9% vs. 11.5%; HR 0.69, 95% CI 0.57 to 0.83) Significant decrease in CV death, MI or CVA (9.9% vs. 12.2%; HR 0.8, 95% CI 0.67 to 0.95) Safety outcomes No significant differences in serious adverse events, including lower-limb amputation and fracture. Conclusion In patients with T2DM and kidney disease, canagliflozin was superior to placebo with respect to the incidence of ESRD, doubling of creatinine, renal death, or CV death. Reference Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. Open reference URL https://web.pathway.md/studies/recNvS32Ff41qxbEc 2/2